Neurolixis Inc., a Park Ridge-based clinical-stage biopharmaceutical company, has announced promising results from its Phase 2A clinical trial of NLX-112 (befiradol) for Parkinson’s disease. Published in Movement Disorders, the study highlights NLX-112 as a potential first-in-class, non-dopaminergic therapy that effectively reduces both levodopa-induced dyskinesia (LID) and motor impairment in Parkinson’s patients.
The randomized, double-blind, placebo-controlled trial, supported by The Michael J. Fox Foundation and Parkinson’s UK, met its primary safety and tolerability endpoints while also demonstrating significant reductions in LID and improved motor function. Unlike traditional dopamine-based therapies, NLX-112 targets the serotonin (5-HT) system, offering a novel treatment approach for Parkinson’s and other movement disorders.
Neurolixis CEO Dr. Adrian Newman-Tancredi described the results as a potential “paradigm shift” in Parkinson’s treatment. The company is now planning the next phase of clinical development to advance NLX-112 toward regulatory approval.
